Syndicate content

Archive - Apr 19, 2009


Novel Drug Targeted at Cancer Stem Cells Shows Promise in Pancreatic Cancer

The combination of a novel drug (tigatuzumab) directed against pancreatic cancer stem cells, and the drug (gemcitabine) currently used for the treatment of pancreatic cancer, has shown promising results in achieving tumor remission and preventing recurrence. Tigatuzumab is a humanized antibody directed against death receptor-5, which the researchers showed is overexpressed in pancreatic cancer stem cells. In the studies, ten patient-derived tumors were implanted in laboratory mice and the effects of the combination therapy were evaluated. Treatment with gemcitabine and tigatuzumab resulted in the reduction of pancreatic cancer stem cells, caused tumor remission, and significantly increased time-to-tumor progression in fifty percent of treated cases from a median of 54 days to 103 days. These results were obtained by researchers from Johns Hopkins and colleagues, and will be presented at the annual AACR meeting April 18-22. [Press release]

Nine New X-Chromosome Genes Associated with Learning Disabilities

Researchers have identified nine new genes on the X-chromosome that, when mutated, are associated with learning disabilities. "We sequenced 720 out of the approximately 800 known genes on the X chromosome in more than 200 families affected by X-linked learning disabilities," explained Professor Michael Stratton, from the Wellcome Trust Sanger Institute. "This is the largest sequencing study of complex disease ever reported." Learning disability is significantly more common in males than in females, and genetic causes have long been sought on the X-chromosome as males have only one X chromosome and so a gene mutation on the X is more likely to have an effect in males than in females. These new findings are expected to aid the diagnoses of X-linked learning disabilities and to enable more comprehensive genetic counseling. [Press release] [Nature Genetics abstract]